A5042277378- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
- Liver Disease Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Drug-Induced Hepatotoxicity and Protection
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis C virus research
- Cutaneous lymphoproliferative disorders research
- CNS Lymphoma Diagnosis and Treatment
- MRI in cancer diagnosis
- Advanced Neuroimaging Techniques and Applications
- Cancer-related molecular mechanisms research
- Virus-based gene therapy research
- Hepatitis B Virus Studies
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Liver Disease and Transplantation
- Galectins and Cancer Biology
Guangxi Medical University
2009-2025
Tumor Hospital of Guangxi Medical University
2021-2025
Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin with limited treatment options. This phase II study evaluated the efficacy safety sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL.Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months until progression, death, withdrawal. The primary end point was objective response rate (ORR) assessed by independent radiologic...
Abstract Purpose: To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. Patients Methods: Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary outcome for study objective response...
Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- lymphomas, but as a drug class, these agents have frequently been observed tolerability limitations. Next-generation that improve the while maintaining efficacy are desirable.
7007 Background: Sintilimab monotherapy for cHL in third-line setting and beyond has been evaluated a single-arm, phase 2 study ORIENT-1. Here, we present results of the 3 ORIENT-21 evaluating sintilimab plus ICE versus placebo as second-line treatment cHL. Methods: This enrolled pts who have failed first-line standard chemotherapy. The safety run-in to enroll receiving ICE, followed by randomized which were assigned 1:1 ratio receive either (experimental arm) or (control 6 cycles. Patients...
7013 Background: Patients (pts) with transplant-ineligible r/r DLBCL have an unmet need, objective response rate (ORR) of around 40%. CD79b, a key component the B-cell receptor and expressed in majority mature malignancies origin, is attractive therapeutic target for DLBCL. We initiated phase 1b/2 study to assess safety efficacy SHR-A1912, novel CD79b-targeted ADC, combination chemotherapy pts or treatment-naive Here, we report findings SHR-A1912 plus R-GemOx regimen cohort. Methods: The...
In patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL), a phase 3 trial was carried out to evaluate the efficacy and safety of zuberitamab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone; Hi-CHOP) versus rituximab (R-CHOP) treatment regimens.
This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) rituximab (Mabthera® ) combined with CHOP as first-line treatment for Chinese patients CD20-positive diffuse large B cell lymphoma (DLBCL). is a randomized, patient-blind, multicenter, active-control, non-inferiority parallel design. Patients were randomly (2:1) to receive (S-CHOP) or (R-CHOP) up 6 cycles. The primary endpoint was Independent Review Committee (IRC) assessed objective response rate (ORR) in...
7531 Background: PI3Kδ inhibitors have been shown to important roles in blocking mitogenic and survival signaling within the tumor cell microenvironment activate antilymphoma immune responses. Linperlisib is an oral highly selective small molecule inhibitor of has demonstrated be well-tolerated with a favorable PK profile patients lymphomas at RP2D. This phase Ib study evaluating efficacy safety relapsed or refractory peripheral T-cell lymphoma (PTCL), aggressive malignancy few treatment...
Abstract The diagnostic efficiency of diffusion-weighted magnetic resonance imaging with different b -values and application an intravoxel incoherent motion (IVIM) model for differentiating disease states lymphoma was investigated. Thirty-six patients at initial diagnosis 69 after chemotherapy underwent (DW-MRI) multiple -values. Analysis parameters included the apparent diffusion coefficient (ADC) each -value. Standard ADC, D , ∗, f were calculated using IVIM model. For diagnosis, compared...
<div>AbstractPurpose:<p>Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- lymphomas, but as a drug class, these agents have frequently been observed tolerability limitations. Next-generation that improve the while maintaining efficacy are desirable.</p>Patients Methods:<p>A phase Ib clinical study was conducted...
<p>Figure and Tables</p>
Background: specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodgkin’s Lymphoma) are limited, as well prophylactic antiviral therapy for patients with HBV who receiving anticancer chemotherapy. This study aims to investigate the association between B-NHL, evaluate effect of HBV-infected patients. Study design: A retrospective, case-control was performed. The group included 420 were consecutively diagnosed from May 2003 October 2013 (age range, 14 - 71 years),...
<div>AbstractPurpose:<p>To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.</p>Patients Methods:<p>Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary...
<p>Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator</p>